AVAI (Avai Bio) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2025)


AVAI Avai Bio Inc AVAI
24 GF Score
Price $0.15
! 3 Warning Signs
View Full Analysis

What is Avai Bio ROE % Adjusted to Book Value?

Avai Bio AVAI -3.77% 24 ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Avai Bio's ROE % for the quarter that ended in Dec. 2025 was 0.00%. Avai Bio's PB Ratio for the quarter that ended in Dec. 2025 was N/A. Avai Bio's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was N/A.

Avai Bio ROE % Adjusted to Book Value Related Terms

Avai Bio ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Avai Bio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avai Bio ROE % Adjusted to Book Value Chart

Avai Bio Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Avai Bio Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 Negative Equity 0.00 0.00 0.00

AVAI vs IPM, RCT, LPSN: ROE % Adjusted to Book Value Comparison

For the Software - Application subindustry, Avai Bio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avai Bio ROE % Adjusted to Book Value vs Software Industry

For the Software industry and Technology sector, Avai Bio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Avai Bio's ROE % Adjusted to Book Value falls into.


AVAI
24GF Score
Avai Bio Inc AVAI
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avai Bio ROE % Adjusted to Book Value Calculation

Avai Bio's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Avai Bio's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Avai Bio (AVAI) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Avai Bio and its competitors.
Is Avai Bio's ROE % Adjusted to Book Value too high?
Avai Bio's current ROE % Adjusted to Book Value is 0.00%. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's ROE % Adjusted to Book Value compare to IPM and RCT?
Avai Bio's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Software company?
A good ROE % Adjusted to Book Value depends on the Software industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Avai Bio and its competitors. Avai Bio's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Avai Bio (AVAI), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avai Bio Business Description

Address 5348 Vegas Drive, Las Vegas, NV, USA, 89108
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score

Get the complete analysis for AVAI

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price